ZYME•globenewswire•
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Summary
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 11, 2026 by globenewswire